Instem Life Sciences, a software provider to the healthcare industry, said several contracts needed to meet revenue and profit expectations for the year remain pending.
The group, which previously cautioned that research organisations, which make up the bulk of its client base, are being cautious in software investment, has seen its share price plunge 57% in the last 12 months.
In its update on trading for the year ending December 31st 201 Instem added that their clients' ability to contribute to current year results will only be known definitively at the year-end.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
As a result, Instem now intends to announce its planned trading update in early January.
Shares of Instem fell 2.2% at 08:40 in London.
CJ
-
Christmas at Chatsworth: review of The Cavendish Hotel at BaslowMoneyWeek Travel Matthew Partridge gets into the festive spirit at The Cavendish Hotel at Baslow and the Christmas market at Chatsworth
-
Tycoon Truong My Lan on death row over world’s biggest bank fraudProperty tycoon Truong My Lan has been found guilty of a corruption scandal that dwarfs Malaysia’s 1MDB fraud and Sam Bankman-Fried’s crypto scam
